Back
Edge
StocktwitsEarnings
Official STOCKTWITS Representative
symbol logo$VXRT Q2 '26 Earnings Results & Recap Vaxart reported total revenue of $27.2 million for the quarter ended June 30, 2026, and a net loss of $13.5 million, with cash, cash equivalents, and short-term investments of $64.0 million.
3
1
6

Price since post

Full Details
Top Replies
LuckyLee
Vaxart CEO Steve Lo and the BOD's need to put their "Boy Pants" and get the ball rolling faster and get their VAAST Oral Pill Vaccines for Corvid-19, Norovirus, Flu, RSV, etc approved by FDA and get it Commercialized so many lives can be saved ASAP..! Where is RFK? He should be pushing for Vaxart’s platform to get approved ASAP.
5
TahoeandChief
decreased liquidity? More like decreased dilution. Which to the already beaten down SHs is a good thing. Make them work for actual deals and not just free money on the backs of naive and optimistic retail.
4
Gordon99
still not bad funding of trial considering the enrollment number was cut in half but the funding was not
2

Advertisement|Remove ads.